President Donald Trump's new European tariffs may spell bad news for Novo Nordisk, maker of Ozempic and Wegovy. As Axios ...

A five-year experiment aims to open access to blockbuster GLP‑1 drugs for obesity, something advocates have pushed for years.

Blockbuster weight loss drugs like Wegovy and Zepbound have surged in popularity, but high prices have left them out of reach for many obese Americans.

The Trump administration is considering a shift in health care coverage, allowing Medicare and Medicaid to cover GLP-1 weight loss drugs.

Proposed experiment would allow states and Medicare drug plans to cover GLP-1 drugs like Ozempic and Wegovy for obesity, The ...

Weight loss medications like Wegovy can be life-changing for people living with obesity or excess weight with related health ...

The Trump administration is planning an experiment to cover weight loss drugs under Medicare and Medicaid, potentially ...

Have a sex or relationship question? Ask Rachel about it using the form below or email [email protected] ...

A trial of Eli Lilly and Co.’s blockbuster diabetes drug Mounjaro fell short of expectations in one aspect, but the results ...

With the use of these medications to help with weight loss and diabetes comes many questions about the long-term impact on ...

A variety of GLP-1 drugs that were developed to treat Type 2 diabetes, including Novo Nordisk’s Ozempic, have secured label ...

GLP-1 drugs like Ozempic are transforming weight loss, but a new UVA study warns they're not improving a critical measure of ...